Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 14 for:    CALM-2
Previous Study | Return to List | Next Study

CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™ (CALM-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03179800
Recruitment Status : Active, not recruiting
First Posted : June 7, 2017
Last Update Posted : January 7, 2020
Sponsor:
Information provided by (Responsible Party):
Vascular Dynamics, Inc.

Brief Summary:
The objective of this study is to evaluate the safety and effectiveness of the MobiusHD System in a prospective, randomized, double-blind, sham-controlled multi-center pivotal study.

Condition or disease Intervention/treatment Phase
Hypertension Resistant Hypertension Device: MobiusHD Other: Sham Implantation Not Applicable

Detailed Description:
The objective of this study is to evaluate the safety and effectiveness of the MobiusHD System in a prospective, randomized, double-blind, sham-controlled multi-center pivotal study. Patients with resistant hypertension who remain uncontrolled despite pharmacologic treatment with maximum tolerated, guideline-directed anti-hypertensive pharmacologic therapy will be evaluated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™
Actual Study Start Date : October 19, 2017
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : May 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MobiusHD Implantation
MobiusHD Implantation
Device: MobiusHD
The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.

Sham Comparator: Sham Implantation
Sham Implantation
Other: Sham Implantation
Sham Implantation




Primary Outcome Measures :
  1. Primary Effectiveness Endpoint - Change in mean 24-hr sABP from baseline to 180-day [ Time Frame: 180-day ]
    The primary effectiveness endpoint is change in mean 24-hr ambulatory systolic blood pressure (24hr sABP) from baseline to the 180-day visit.


Other Outcome Measures:
  1. Safety Assessments - Composite measured at 90-day [ Time Frame: 90-day ]
    Composite measure of death, MI, stroke, device embolization, carotid occlusion, new ipsilateral carotid stenosis requiring surgical or percutaneous intervention, or Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding events as adjudicated by CEC from randomization through the 90-day visit. All adverse events.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Mean 24 hour ambulatory systolic blood pressure ≥145 mmHg and ≤200 mmHg and stable for at least 8 weeks on a maximally tolerated guideline directed, (JNC8) or their equivalent when those listed are not available dosing regimen consisting of up to 5 antihypertensive medications, with a minimum required dosing regimen of an "A+C+D" antihypertensive medication regimen, where "A" is an angiotensin-converting enzyme Inhibitor or an angiotensin receptor blocker, "C" is a calcium channel blocker, and "D" is a diuretic.

Exclusion Criteria:

  • Inadequacy of the carotid anatomy for treatment with the MobiusHD based on carotid angiography.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03179800


Locations
Show Show 40 study locations
Sponsors and Collaborators
Vascular Dynamics, Inc.
Investigators
Layout table for investigator information
Study Chair: Bryan Williams, MD University College, London
Study Chair: Gregg Stone, MD Cardiovascular Research and Education Columbia University Medical Center
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Vascular Dynamics, Inc.
ClinicalTrials.gov Identifier: NCT03179800    
Other Study ID Numbers: CRD0447
First Posted: June 7, 2017    Key Record Dates
Last Update Posted: January 7, 2020
Last Verified: January 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Vascular Dynamics, Inc.:
Hypertension
Resistant Hypertension
Baroreceptor
BAT
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases